By Danny Sullivan – Logevity.Technology
Longevity biotech company Rejuveron Life Sciences has successfully closed a dual-tranche Series B equity and convertible loan financing round, raising a total of $75 million. The funding was co-led by Catalio Capital Management and Apeiron Investment Group, the family office and private investment firm of entrepreneur Christian Angermayer. The round was also joined by new investor Mubadala Capital, a subsidiary of Mubadala Investment Company, the $280 billion sovereign investor group headquartered in Abu Dhabi, UAE.
